ConductScience.org, home

Paper41254792

Impact of TauroLock™-HEP500 versus unfractionated heparin for prevention of catheter complications in children with malignancy: a prospective, randomized, controlled study.

Eghbali A and 5 others. Eur J Med Res, 2025. Cited by 2 papers, by iCite.

Cite this record

ConductScience Library. Impact of TauroLock™-HEP500 versus unfractionated heparin for prevention of catheter complications in children with malignancy: a prospective, randomized, controlled study. Papers, record 41254792. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41254792

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Impact of TauroLock™-HEP500 versus unfractionated heparin for prevention of catheter complications in children with malignancy: a prospective, randomized, controlled study.
PubMed
Journal
Eur J Med Res
PubMed
Year
2025
PubMed
Publication types
Journal Article, Randomized Controlled Trial
PubMed
Citations, by iCite
2
iCite
Revised in PubMed
2026-01-27
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Topics18

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
AnticoagulantsMajor topic
Catheter-Related InfectionsMajor topic
Central Venous CathetersMajor topic
HeparinMajor topic
TaurineMajor topic
ThiadiazinesMajor topic
ThrombosisMajor topic
Adolescent
Child
Child, Preschool
Female
Humans
Infant
Male
C-Reactive Protein
Catheterization, Central Venous
Neoplasms
Prospective Studies

Source PubMed

Download CSV of topics

References44

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
115677621Central venous catheter-related complications in children with oncological/hematological diseases: an observational study of 418 devices.Ann Oncol2005https://conductscience.org/library/papers/15677621PubMed
240000988The effect of oral curcumin on vincristine-induced neuropathy in pediatric acute lymphoblastic leukemia: A double-blind randomized controlled clinical trial.BMC Cancer2025https://conductscience.org/library/papers/40000988PubMed
332691665Impact of locking solutions on conditioning biofilm formation in tunnelled haemodialysis catheters and inflammatory response activation.J Vasc Access2021https://conductscience.org/library/papers/32691665PubMed
430729550Human platelet antigens polymorphisms; association to the development of liver fibrosis in patients with chronic hepatitis C.J Med Virol2020https://conductscience.org/library/papers/30729550PubMed
539898322Effects of oral Lcarnitine supplementation on liver enzymes in pediatric acute lymphoblastic leukemia patients in the maintenance phase of treatment: a randomized clinical trial study.Front Pharmacol2024https://conductscience.org/library/papers/39898322PubMed
634148394Taurolidine lock in the treatment of colonization and infection of totally implanted venous access devices in cancer patients.J Vasc Access2023https://conductscience.org/library/papers/34148394PubMed
737075273Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Guideline Update.J Clin Oncol2023https://conductscience.org/library/papers/37075273PubMed
824820084Tunneled catheters with taurolidine-citrate-heparin lock solution significantly improve the inflammatory profile of hemodialysis patients.Antimicrob Agents Chemother2014https://conductscience.org/library/papers/24820084PubMed
936944461
CATERPILLAR-study protocol: an assessor-blinded randomised controlled trial comparing taurolidine-citrate-heparin to heparin-only lock solutions for the prevention of central line-associated bloodstream infections in paediatric oncology patients.
BMJ Open2023https://conductscience.org/library/papers/36944461PubMed
1016601268Cytokines in atherosclerosis: pathogenic and regulatory pathways.Physiol Rev2006https://conductscience.org/library/papers/16601268PubMed
1134767871The efficacy of taurolidine containing lock solutions for the prevention of central-venous-catheter-related bloodstream infections: a systematic review and meta-analysis.J Hosp Infect2022https://conductscience.org/library/papers/34767871PubMed
1225262758Hemodialysis catheter locking solutions and the prevention of catheter dysfunction: a meta-analysis.J Vasc Access2015https://conductscience.org/library/papers/25262758PubMed
1333394637Infusion Therapy Standards of Practice, 8th Edition.J Infus Nurs2021https://conductscience.org/library/papers/33394637PubMed
1424385746MPL W515L/K Mutations in Chronic Myeloproliferative Neoplasms.Turk J Haematol2013https://conductscience.org/library/papers/24385746PubMed
1531145505
Taurolidine-citrate lock solution for the prevention of central line-associated bloodstream infection in paediatric haematology-oncology and gastrointestinal failure patients with high baseline central-line associated bloodstream infection rates.
J Paediatr Child Health2020https://conductscience.org/library/papers/31145505PubMed
1627489590Evaluation of Minimal Residual Disease in Acute Myeloid Leukemia with NPM1 Marker.Int J Hematol Oncol Stem Cell Res2016https://conductscience.org/library/papers/27489590PubMed
1719675528Non-infected hemodialysis catheters are associated with increased inflammation compared to arteriovenous fistulas.Kidney Int2009https://conductscience.org/library/papers/19675528PubMed
1830323092Survivorship, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.J Natl Compr Canc Netw2018https://conductscience.org/library/papers/30323092PubMed
1923269457Successful prevention of tunneled central catheter infection by antibiotic lock therapy using cefazolin and gentamicin.Int Urol Nephrol2013https://conductscience.org/library/papers/23269457PubMed
2031712211A Randomized, Double-Blind, Placebo-Controlled Trial (TAURCAT Study) of Citrate Lock Solution for Prevention of Endoluminal Central Venous Catheter Infection in Neutropenic Hematological Patients.Antimicrob Agents Chemother2020https://conductscience.org/library/papers/31712211PubMed

See all 44 referencesDownload CSV of references

Cited by1

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.

PMIDTitleJournalYearIn Papers
41889023Effects of Clinical Pharmacist-Led Medication Management on Medication Adherence and Quality of Life in Stroke Patients Undergoing Intravenous Thrombolysis.Med Sci Monit2026https://conductscience.org/library/papers/41889023

Source PubMed

Download CSV of cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CRP1401PubTator's text mininghttps://conductscience.org/library/genes/1401NCBI Gene
IL63569PubTator's text mininghttps://conductscience.org/library/genes/3569NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41254792

GET https://conductscience.org/api/papers/v1/41254792/references?page=2